A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment feasibility

Conditions

COVID-19

Interventions

DRUG: RBT-9 (90 mg)
DRUG: 0.9% sodium chloride (normal saline)

Sponsor

Renibus Therapeutics, Inc.